Research Article

Analysis of the Influencing Factors of Sentinel Lymph Node Metastasis in Breast Cancer

Wei Lyu, Yujuan Guo, Haiyan Peng, Nanyu Xie, and Hongyi Gao

Department of Pathology, Guangdong Women and Children Hospital, Guangzhou 511400, China

Correspondence should be addressed to Hongyi Gao; hygao1@hotmail.com

Received 21 June 2022; Revised 11 July 2022; Accepted 15 July 2022; Published 9 August 2022

Academic Editor: Xiaotong Yang

Copyright © 2022 Wei Lyu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To analyze and discuss the influencing factors of sentinel lymph node metastasis in breast cancer. Methods. A total of 469 breast cancer patients admitted in the Department of Pathology of Guangdong Women and Children Hospital from October 2016 to December 2021 were retrospectively analyzed. The general information, immunohistochemical expression, tumor molecular subtype, tumor size, histological grade, pathological type, and tumor location were collected and the relationship with sentinel lymph node metastasis was analyzed. Results. For patients with different age, Ki-67 and Human epidermal growth factor receptor-2 (HER-2) immunohistochemical expression level (invasive cancer), molecular subtype (invasive cancer), tumor size, histological grade (invasive cancer) and pathological type. The results of multivariate logistic regression analysis showed that the age was less than or equal to 40 years; the molecular subtype was Luminal B and HER-2 overexpression (invasive cancer); tumor was larger; the histological grade (invasive cancer) was higher; the pathological type was invasive carcinoma, there were independent risk factors for sentinel lymph node metastasis in breast cancer. The sentinel lymph node metastasis rates of invasive lobular carcinoma, invasive micropapillary carcinoma, and metaplastic carcinoma (all met the criteria for squamous cell carcinoma and histological grade III) were higher than 50% in special invasive carcinomas. Conclusion. Age, expression level of Ki67 and HER-2, molecular typing, tumor volume and histological grade are all high-risk factors related to sentinel lymph node metastasis of breast cancer. When one or more of the above factors are involved in an examination, pathologists should be more cautious in making a sentinel lymph node frozen diagnosis. By standardizing the sampling and increasing the number of frozen sections (slicing more frozen tissue layers), the section quality can be improved. This may be conducive to reducing the false negative rate and reducing the pain and risk of secondary surgery.

1. Introduction

Globally, breast cancer is the most common female malignancy, accounting for approximately one quarter of all cancers, and the incidence remains high [1, 2]. Compared with Europe and the United States, the incidence of the disease has increased in China, especially in rural areas [3–6]. However, due to advances in cancer screening and treatment, breast cancer mortality has declined significantly in recent years [7–9]. At present, the treatment of breast cancer mainly includes surgery, radiotherapy and chemotherapy, endocrine therapy, targeted therapy, and immunotherapy. Although the treatment methods are constantly enriched and the survival rate has improved, the associated adverse reactions still compromise the quality of life of patients. A number of studies have shown that the combination of traditional Chinese and Western medicine in the treatment of breast cancer can reduce the adverse reactions of radiotherapy and chemotherapy, enhance the body’s immunity, effectively prevent the recurrence and metastasis of breast cancer, significantly improve the quality of life of patients, and prolong the survival time of patients. However, there is currently no unified standard for TCM syndrome types of breast cancer, and its application has not been popularized [10].

Originating from the study of penile cancer, the sentinel lymph node (Sentinel lymph node, SLN) refers to the lymph nodes that first metastasize to the tumor, which can be one or a group of lymph nodes. In sentinel lymph node biopsy (SLNB), the lymph nodes are marked with tracers, and after
excision, a pathological examination is performed [11]. When the pathological result of SLNB is negative, dissection of the axillary lymph nodes may not need to be performed to avoid metastasis. It can reduce trauma and significantly improve the quality of life after surgery [12–14]. When the results are positive, axillary lymph node dissection may be necessary.

The pathological diagnosis of SLNB is performed by intraoperative frozen section examination of the sentinel lymph nodes. Due to the limitations of frozen tablets, even with standardized procedures, misdiagnosis still exists, especially for sentinel lymph node micrometastases [15]. Patients may bear the pain and risk of a second surgery. This study analyzed the influencing factors of sentinel lymph node metastasis in breast cancer patients. In the event that there are one or more high-risk factors, pathologists should be more cautious when making a sentinel lymph node frozen diagnosis to reduce the false-negative rate of pathology.

2. Methods and materials

2.1. Baseline Data. The data of the cases of breast cancer diagnosed by the Department of Pathology of Guangdong Women and Children Hospital from October 2016 to December 2021 were reviewed.

2.2. Inclusion Criteria. All punctured or minimally invasive surgeries were treated with immunohistochemical estrogen receptor (ER), progesterone receptor (PR), Ki-67, and human epidermal growth factor receptor-2 (HER-2). All cases underwent intraoperative sentinel lymph node frozen section examination after confirmation. All cases were primary breast tumors, and none of the patients received neoadjuvant therapy.

2.3. Data Collection Method. The patient’s age, immunohistochemical expression, tumor molecular subtype, tumor size, histological grade, pathological type, tumor location, and other clinical and pathological data were queried and collected through the pathological diagnosis system and electronic medical record system. Four hundred and sixty-nine cases of standardized breast cancer were included.

2.4. Statistical Analysis. All data were processed by SPSS 19.0 software. According to the nature of the data and the purpose of the study, chi square analysis and multivariate logistic regression analysis were performed. P values < 0.05 were deemed as significant.

3. Results

3.1. Sentinel Lymph Node Metastasis of Breast Cancer. A total of 469 cases of breast cancer were included, including 41 cases (8.74%) of breast carcinoma in situ, no cancer metastasis in sentinel lymph nodes (0.00%); There were 428 cases of breast invasive carcinoma (91.26%) and 139 cases of sentinel lymph node metastasis (32.48%).

3.2. Univariate Analysis of Sentinel Lymph Node Metastasis. The results indicated that there were significant differences in sentinel lymph node metastasis rates among breast cancer patients of different ages, Ki-67 and HER-2 immunohistochemical expression levels (invasive carcinoma), molecular subtypes (invasive carcinoma), tumor size, histological grade (invasive carcinoma) and pathological types (P < 0.05) as shown Table 1.

3.3. Multivariate Logistic Regression Analysis of Influencing Factors of Sentinel Lymph Node Metastasis. Using sentinel lymph node metastasis as a dependent variable, age, Ki-67 (IHC), HER-2 (IHC), molecular subtype, tumor size, histological grade, and pathological type as independent variables, multivariate logistic regression analysis was performed. See Table 2 for assignment of independent variables. The results indicated that age ≤ 40, molecular subtypes of luminal B and HER-2 overexpression (infiltrating carcinoma), the larger the tumor, the higher the histological grade (infiltrating carcinoma), and the pathological type of infiltrating carcinoma were independent risk factors for sentinel lymph node metastasis of breast cancer (P < 0.05). See Table 3.

3.4. Sentinel Lymph Node Metastasis of Special Invasive Carcinoma. The sentinel lymph node metastasis rate of invasive lobular carcinoma, invasive micropapillary carcinoma, and metaplastic carcinoma (all conform to squamous cell carcinoma, histological grade III) in special invasive carcinoma was higher than 50%. See Table 4.

4. Discussion

Sentinel lymph node metastasis is related to surgical method choice and prognosis [11, 12]. Intraoperative frozen section examination can determine the status of sentinel lymph nodes, but due to limitations, there is a false negative rate of about 10% [18]. If the associated high-risk factors are noted, better preparation for frozen collection and frozen section may reduce the false-negative rate of pathology.

This study suggested that when the patient was less than or equal to 40 years old, the immunohistochemical expression level of Ki-67 and HER-2 was higher (invasive cancer), the molecular subtype was Luminal B and HER-2 overexpression (invasive cancer), the tumor was larger, histological grade (invasive cancer) was higher, and the pathological type included invasive lobular carcinoma, invasive micropapillary carcinoma, metaplastic carcinoma. We should consider these to be high-risk factors for sentinel lymph node metastasis.

In this study, in the age ≤ 40 group, the sentinel lymph node metastasis rate was about 40.54%, and in the age > 40 groups was about 27.59%. Patients aged less than or equal to 40 were defined as young breast cancer patients [16] and had more adverse prognostic factors compared with middle-aged and elderly patients, including larger lesions, poor differentiation, HER-2 overexpression, triple negative type and vascular invasion are more common, have higher
Table 1: Univariate analysis (n (%)).

| Interfering factors          | n     | No metastasis | With metastasis | χ²   | P      |
|------------------------------|-------|---------------|-----------------|------|--------|
| Age ≤40                      | 74    | 44 (59.46)    | 30 (40.54)      | 5.01 | 0.03   |
| Age >40                      | 395   | 286 (72.41)   | 109 (27.59)     |      |        |
| Ki-67 ≤30%                   | 196   | 153 (78.06)   | 43 (21.94)      | 24.93| ≤0.01  |
| Ki-67 30%–60%                | 114   | 76 (66.67)    | 38 (33.33)      |      |        |
| Ki-67 >60%+                  | 118   | 60 (50.85)    | 58 (49.15)      |      |        |
| HER-2 Negative               | 196   | 151 (77.04)   | 45 (22.96)      | 19.52| ≤0.01  |
| HER-2 Unsure                 | 172   | 109 (63.37)   | 63 (36.63)      |      |        |
| HER-2 Positive               | 60    | 29 (48.33)    | 31 (51.67)      |      |        |
| Molecular subtype            |       |               |                 |      |        |
| Luminal A                    | 161   | 124 (77.02)   | 37 (22.98)      | 21.90| ≤0.01  |
| Luminal B                    | 166   | 95 (57.23)    | 71 (42.77)      |      |        |
| HER-2 expression             | 48    | 27 (56.25)    | 21 (43.75)      |      |        |
| Sanyin type                  | 53    | 43 (81.13)    | 10 (18.87)      |      |        |
| Size of tumor                |       |               |                 |      |        |
| ≤2 cm                        | 234   | 176 (75.21)   | 58 (24.79)      | 7.26 | 0.03   |
| 2–5 cm                       | 219   | 146 (66.67)   | 73 (33.33)      |      |        |
| >5 cm                        | 16    | 8 (50.00)     | 8 (50.00)       |      |        |
| Histological grade           |       |               |                 |      |        |
| I                            | 93    | 87 (93.55)    | 6 (6.45)        | 39.90| ≤0.01  |
| II                           | 251   | 158 (62.95)   | 93 (37.05)      |      |        |
| III                          | 84    | 44 (52.38)    | 40 (47.62)      |      |        |
| Pathological type            |       |               |                 |      |        |
| Carcinoma in situ            | 41    | 41 (100.00)   | 0 (0.00)        | 22.11| ≤0.01  |
| Nonspecific                  | 369   | 238 (64.50)   | 131 (35.50)     |      |        |
| Specific                     | 59    | 36 (61.02)    | 23 (38.98)      |      |        |
| Region                       |       |               |                 |      |        |
| Outer upper quadrant         | 201   | 136 (67.66)   | 65 (32.34)      | 6.41 | 0.17   |
| Outer lower quadrant         | 77    | 58 (75.32)    | 19 (24.68)      |      |        |
| Inner upper quadrant         | 97    | 74 (76.29)    | 23 (23.71)      |      |        |
| Inner lower quadrant         | 36    | 27 (75.00)    | 9 (25.00)       |      |        |
| Posterior papilla            | 58    | 35 (60.34)    | 23 (39.66)      |      |        |

Note. The pathological molecular subtypes and histological grades of breast cancer are only analyzed for the components of invasive breast cancer. Because no sentinel lymph node metastasis occurred in breast carcinoma in situ, in order to eliminate its interference, factors such as “Ki-67 (IHC),” HER-2 (IHC) “only analyzed cases of invasive breast cancer.

Table 2: Assignment of multivariate logistic regression analysis.

| Factors                  | Evaluation                                                                 |
|--------------------------|---------------------------------------------------------------------------|
| Age ≤40; >40             | 1; 2                                                                       |
| Ki-67 (IHC) ≤30%; 30%–60%; >60%+ | 1; 2; 3                                                                   |
| HER-2 (IHC)              | Negative = 1; Unsure = 2; Positive = 3                                     |
| Molecular subtype        | Luminal A = 1; luminal B = 2; HER-2+ = 3; sanyin type = 4                 |
| Size of tumor            | ≤2 cm = 1; 2–5 cm = 2; >5 cm = 3                                           |
| Histological grading     | I = 1; II = 2; III = 3                                                    |
| Pathological type        | Carcinoma in situ = 1; nonspecific = 2; special = 3                      |

Table 3: Multivariate logistic regression analysis.

| Influential factors | B     | SE     | Wald χ² | P   | OR     | 95% CI           |
|---------------------|-------|--------|---------|-----|--------|------------------|
| Age                 | 0.760 | 0.227  | 11.256  | 0.001| 2.139  | (1.372, 3.336)   |
| Ki-67 (IHC)         | 0.226 | 0.133  | 2.895   | 0.089| 1.254  | (0.966, 1.626)   |
| HER-2 (IHC)         | -0.052| 0.132  | 0.156   | 0.693| 0.949  | (0.734, 1.229)   |
| Molecular subtype   | -0.290| 0.099  | 8.624   | 0.003| 0.748  | (0.616, 0.908)   |
| Tumor size          | -0.554| 0.140  | 15.724  | ≤0.001| 0.575  | (0.437, 0.756)   |
| Histological grading| 0.279 | 0.134  | 4.364   | 0.037| 1.322  | (1.017, 1.717)   |
| Pathological type   | 0.332 | 0.134  | 6.117   | 0.013| 1.394  | (1.071, 1.814)   |
histological grades, are more prone to lymph node metastases, and have more metastases [17, 18]. Presumably, young breast cancer patients have high levels of endogenous estrogen in the blood. They tend to develop rapidly after developing breast cancer, the disease is mostly in the advanced stage, and it is more likely to have axillary lymph node metastasis, blood or bone metastasis in the early stage [19]. In addition, young breast cancer patients are at reproductive age, their clinical symptoms are not typical, and the physiological hyperplasia of breast cancer patients are at reproductive age, their clinical symptoms are not typical, and the physiological hyperplasia and development of the breast make the tumor difficult to discover on their own. Together, the late treatment, the dense breast gland tissue, and the low sensitivity of B-ultrasound and mammography are also the influencing factors.

Ki-67 is a nuclear protein that is expressed in various stages of cell proliferation (G1, S, G2, M), but not in cell quiescence (G0). Therefore, Ki-67 can detect the proliferation activity of normal tissue and tumor tissue. The higher the Ki-67 index, the more aggressive the breast cancer and the worse the prognosis [18, 20]. HER-2 is a tyrosine kinase transmembrane protein involved in the regulation of multiple intracellular signaling pathways and is associated with breast cancer cell proliferation and apoptosis. HER-2 positive with obvious nuclear atypia, poor tumor differentiation, and high number of lymph node metastases, are associated with poor prognosis of patients [18, 21]. Our findings were similar to the above findings.

According to St Gallen [22], breast cancer is divided into four molecular subtypes, including ① luminal A: ER positive, HER-2 negative, Ki67 < 14%, or Ki67 at 14%–19% and PR>20%; ② luminal B: ER positive, HER-2 negative, Ki67 > 20%, or Ki67 at 14%–19% and PR negative or PR<20%, or ER positive, HER-2 positive; ③ HER-2 overexpression: ER negative, PR negative, and HER-2 positive; ④ triple negative: ER negative, PR negative, HER-2 negative. In this study, the molecular subtypes Luminal B and HER-2 overexpressed sentinel lymph node metastasis rates were higher (42.77% and 43.75%, respectively), compared with Luminal A (22.98%) and triple negative (18.87%). Similar to the findings of Wang Kanghan [23], this may be related to the higher expression levels of Ki67 or HER-2 in the molecular subtype Luminal B and HER-2 overexpression. Relevant studies [24, 25] showed that breast cancer tumor size was positively correlated with lymph node metastasis, which may be because the larger the tumor size, the more likely it is to have invasive cancer and the greater the possibility of invading vessels. Some patients received neoadjuvant therapy before surgery, which affected the actual size of the tumor and lymph node status, so these cases were excluded from this study. The results of this study showed that with the enlargement of the tumor, the rate of sentinel lymph node metastasis increased.

Breast cancer was histologically graded by assessing the degree of tubular and glandular differentiation, nuclear pleomorphism, and mitotic counts in invasive carcinomas. With these indicators, the histological grade of breast cancer is significantly correlated with the prognosis of patients [26, 27]. The severity of tumor differentiation, nuclear atypia, mitotic figures, and lymph node metastasis rates varies from grade I to grade III in histological grades. This study showed that the sentinel lymph node metastasis rate of breast cancer with histological grade I was 6.45%, that of grade II was 37.05%, and that of grade III was 47.62%.

Invasive lobular carcinoma accounts for approximately 5–15 percent of invasive breast cancers, and studies showed that there were more lymph node metastases than non-specialized invasive carcinomas [28]. This may be related to the loss of E-cadherin expression in invasive lobular carcinoma. E-cadherin is a cadherin, which can maintain intercellular adhesion and cell polarity. When the tumor tissue lacks or expresses low E-cadherin, it indicates aggressive [29]. Invasive micropapillary carcinoma accounts for approximately 3–8 percent of invasive breast cancers [30] and has a high rate of axillary lymph node metastasis [31]. Under electron microscopy, invasive micropapillary carcinoma cells have abnormally abundant filaments in the cytoplasm, which are highly mobile and invasive. In addition, cancer cells have been observed to contact the vascular endothelium through microvilli, which may be involved in tumor metastasis [32]. Metaplastic carcinomas are a group of tumors characterized by tumor epithelial differentiation to squamous and/or mesenchymal elements. Two cases of metaplastic carcinoma in this study all met the criteria for squamous cell carcinoma and histological grade III. Sentinel lymph node metastasis was observed in both cases.

There are still several limitations in this study. First, this study is a retrospective research analysis, and the retrospective study itself has certain defects; second, the sample size of this study is too small, it lacks representativeness, and the results might lack generalizability, which may bias the conclusion.

### Table 4: Sentinel lymph node metastasis of special invasive carcinoma (n (%)).

| Special invasive carcinoma | n   | No metastasis | Metastasis |
|----------------------------|-----|---------------|------------|
| Invasive lobular carcinoma | 10  | 3 (30.00)     | 7 (70.00)  |
| Tubular carcinoma          | 5   | 5 (100.00)    | 0 (0.00)   |
| Cribriform carcinoma       | 2   | 2 (100.00)    | 0 (0.00)   |
| Mucinous carcinoma         | 20  | 19 (95.00)    | 1 (5.00)   |
| Invasive micropapillary carcinoma | 15 | 4 (26.67)    | 11 (73.33) |
| Carcinoma with apocrine differentiation | 5 | 3 (60.00) | 2 (40.00) |
| Metaplastic carcinoma      | 2   | 0 (0.00)      | 2 (100.00) |

Note: the tumors in the table are sorted according to the catalog of breast tumors.

5. Conclusion

Age, expression level of Ki 67 and HER-2, molecular typing, tumor volume, and histological grade are all high-risk...
factors related to sentinel lymph node metastasis of breast cancer. When one or more of the above factors are involved in an examination, pathologists should be more cautious in making a sentinel lymph node frozen diagnosis. By standardizing the sampling and increasing the number of frozen sections (slicing more frozen tissue layers), the section quality can be improved. This may be conducive to reducing the false negative rate and reducing the pain and risk of secondary surgery.

Data Availability
No data were used to support this study.

Conflicts of Interest
The authors declare that there are no conflicts of interest.

Acknowledgments
The study was supported by The Research Project Program of Traditional Chinese Medicine Bureau of Guangdong Province (No. 20221048).

References
[1] S. Jin, D. Liang, lidaojuan et al., “Study on the global prevalence of female breast cancer,” Chinese Journal of oncology, vol. 26, no. 9, pp. 683–690, 2017.
[2] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: A Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, 2018.
[3] J. Ferlay, M. Colombet, I. Soerjomataram et al., “Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018,” European Journal of Cancer, vol. 103, pp. 356–387, 2018.
[4] R. L. Siegel, K. D. Miller, H. E. Fuchs, and A. Jemal, “Cancer statistics, 2022,” CA: A Cancer Journal for Clinicians, vol. 72, no. 1, pp. 7–33, 2022.
[5] C. E. Desantis, J. Ma, M. M. Gaudet et al., “Breast cancer statistics, 2019,” CA: A Cancer Journal for Clinicians, vol. 69, pp. 1–14, 2019.
[6] Hemingyanzhubiqi Zhongyuan et al., “Analysis on the incidence and death trend of female breast cancer in China from 2005–2013,” Chinese Journal of disease control, vol. 23, no. 1, pp. 10–14, 2019.
[7] C. E. DeSantis, J. Ma, A. Goding Sauer, L. A. Newman, and A. Jemal, “Breast cancer statistics, 2017, racial disparity in mortality by state,” CA: A Cancer Journal for Clinicians, vol. 67, no. 6, pp. 439–448, 2017.
[8] G. Carioli, M. Malvezzi, T. Rodriguez, P. Bertuccio, E. Negri, and C. La Vecchia, “Trends and predictions to 2020 in breast cancer mortality in Europe,” The Breast, vol. 36, pp. 89–95, 2017.
[9] G. Carioli, M. Malvezzi, T. Rodriguez, P. Bertuccio, E. Negri, and C. La Vecchia, “Trends and predictions to 2020 in breast cancer mortality: americas and Australasia,” The Breast, vol. 37, pp. 163–169, 2018.
[10] M. J. Heins, K. M. de Ligt, J. Verloop et al., “Adverse health effects after breast cancer up to 14 years after diagnosis,” The Breast, vol. 61, pp. 22–28, 2022.
[11] “Breast surgery group, branch of surgery, Chinese Medical Association Clinical practice guide for sentinel lymph node biopsy in early breast cancer in China (2022),” Chinese Journal of Practical Surgery, vol. 42, no. 2, pp. 137–145, 2022.
[12] J. Tang, S. Ding, Y. Wu et al., “The diagnostic value of SLNB in patients with axillary lymph node metastasis of early breast cancer and its effect on reducing postoperative complications and improving patients’ quality of life,” Journal of Hunan Normal University (Medical Edition), vol. 18, no. 6, pp. 141–144, 2021.
[13] G. Manca, D. Rubello, E. Tardelli et al., “Sentinel lymph node biopsy in breast cancer: indications, contraindications, and controversies[1],” Clinical Nuclear Medicine, vol. 41, no. 2, pp. 126–133, 2016.
[14] P. Veronesi and G. Corso, “Standard and controversies in sentinel node in breast cancer patients,” The Breast, vol. 48, no. 1, pp. 553–556, 2019.
[15] J. Boniface, J. Frisell, L. Bergkvist, and Y. Andersson, “Breast-conserving surgery followed by whole-breast irradiation offers survival benefits over mastectomy without irradiation,” British Journal of Surgery, vol. 105, no. 12, pp. 1607–1614, 2018.
[16] S. Paluch-Shimon, O. Pagani, A. H. Partridge et al., “ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3),” Breast, vol. 35, pp. 203–217, 2017.
[17] B. Radecka and M. Litwiniuk, “Breast cancer in young women,” Ginekologia Polska, vol. 87, no. 9, pp. 659–663, 2016.
[18] C. Cuilifang, H. Chang et al., “Clinicopathological characteristics of invasive ductal carcinoma and its molecular subtypes in young women,” Journal of diagnostic pathology, vol. 28, no. 7, pp. 562–571, 2021.
[19] D. Germain, “Estrogen carcinogenesis in breast cancer,” Endocrinology and Metabolism Clinics of North America, vol. 40, no. 3, pp. 473–484, 2011.
[20] F. Petrelli, G. Viale, M. Cabiddu, and S. Barni, “Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64, 196 patients,” Breast Cancer Research and Treatment, vol. 153, no. 3, pp. 477–491, 2015.
[21] H. Abdel-Razeq, H. Almasri, F. Abdel Rahman et al., “Sentinel node biopsy for patients with different molecular types of breast cancer [j],” ESMO 3rd International Consensus Guidelines for Breast Cancer 2013, pp. 4102–4108, 2017.
[22] J. Ding, L. Jiang, and W. Wu, “Predictive value of clinicopathological characteristics for sentinel lymph node metastasis in early breast cancer,” Journal of diagnostic pathology, vol. 24, no. 9, pp. 2206–2223, 2013.
[23] K. Wang and L. Y. Guochenxu, “Qian Jun Study on axillary lymph node metastasis and its correlation with prognosis in patients with different molecular types of breast cancer [j],” Journal of Gannan Medical College, vol. 40, no. 2, pp. 169–172, 2020.
[24] J. Ding, L. Jiang, and W. Wu, “Predictive value of clinicopathological characteristics for sentinel lymph node metastasis in early breast cancer,” Medical Science Monitor, vol. 23, pp. 4102–4108, 2017.
[25] Goubin Analysis of related factors of axillary lymph node metastasis in patients with breast cancer,” Journal of Bengbu Medical College, vol. 46, no. 2, pp. 206–213, 2021.
[26] E. A. Rakha, J. S. Reis-Filho, F. Baehner et al., “Breast cancer prognostic classification in the molecular era: the role of
histological grade,” *Breast Cancer Research*, vol. 12, no. 4, p. 207, 2010.

[27] E. A. Rakha, M. E. El-Sayed, A. H. S. Lee et al., “Prognostic significance of Nottingham histologic grade in invasive breast carcinoma,” *Journal of Clinical Oncology*, vol. 26, no. 19, pp. 3153–3158, 2008.

[28] C. I. Li, D. J. Uribe, and J. R. Daling, “Clinical characteristics of different histologic types of breast cancer,” *British Journal of Cancer*, vol. 93, no. 9, pp. 1046–1052, 2005.

[29] Liu Yuan Expression and clinical significance of Topo, "Ki67 and E-cadherin in breast cancer," *Journal of Harbin Medical University*, vol. 50, no. 6, pp. 548–550, 2016.

[30] Y. L. Yang, B. B. Liu, X. Zhang, and L. Fu, "Invasive micropapillary carcinoma of the breast: an update," *Archives of Pathology & Laboratory Medicine*, vol. 140, no. 8, pp. 799–805, 2016.

[31] X. Guo, L. Chen, R. Lang, Y. Fan, X. Zhang, and L. Fu, "Invasive micropapillary carcinoma of the breast: association of pathologic features with lymph node metastasis," *American Journal of Clinical Pathology*, vol. 126, no. 5, pp. 740–746, 2006.

[32] S. Luna-More, B. Gonzalez, C. Acedo, I. Rodrigo, and C. Luna, "Invasive micropapillary carcinoma of the breast. A new special type of invasive mammary carcinoma," *Pathol Res Pract*, vol. 190, no. 7, pp. 668–674, 1994.